2016
DOI: 10.1016/j.compbiomed.2016.03.002
|View full text |Cite
|
Sign up to set email alerts
|

Identification of mutated driver pathways in cancer using a multi-objective optimization model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
27
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 22 publications
(27 citation statements)
references
References 36 publications
0
27
0
Order By: Relevance
“…In the experiments, real biological datasets as well as simulated ones were leveraged to compare the identification performance of the Dendrix [12], the GA [14], the iMCMC [15], the MOGA [16], the PGA-MWS [17]…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In the experiments, real biological datasets as well as simulated ones were leveraged to compare the identification performance of the Dendrix [12], the GA [14], the iMCMC [15], the MOGA [16], the PGA-MWS [17]…”
Section: Resultsmentioning
confidence: 99%
“…Zhang et al [15] presented a network-based approach iMCMC by integrating copy number variations (CNVs), somatic mutations, and gene expressions. Zheng et al [16] devised a more reliable algorithm MOGA by coordinating high coverage and high mutual exclusivity. Recently, Wu et al [17] redefined the model of the maximum weight submatrix problem, modulating coverage and mutual exclusivity by using the average weight of genes in one pathway.…”
Section: Introductionmentioning
confidence: 99%
“…One of the challenges of cancer treatment is how to identify tumor subtypes, which can help to provide patients with specific treatment. Meanwhile, with the continuous development of all kinds of sequencing technologies, a lot of high flux data have been produced (Zheng et al 2016). For cancer subtypes identification, integration of different types of omics data to unravel the molecular mechanism of complex diseases becomes more and more important (Zhang et al, 2016).…”
Section: Introductionmentioning
confidence: 99%
“…Functionally related driver mutations in the genome, also known as driver modules or pathways, activate the mechanisms by which cancer occurs, triggering cancer, driving cancer progression and giving cancer cells a selective advantage. Some computational methods and mathematical models have been developed to detect driver gene sets, pathways and modules by using large-scale sequencing data (Hou et al, 2016;Zheng et al, 2016;Yang et al, 2017;Xi et al, 2018;Ahmed et al, 2019;Deng et al, 2019;Zhang and Wang, 2019a;Pelegrina et al, 2020). Existing research show that the members of cancer driver modules often exhibit specific mutation patterns in cancer samples, the most significant characteristic is mutual exclusivity (mutex) which means once one member mutates, the tumor will gain a significant selection advantage, while later mutations in other members will not give the tumor a selection advantage.…”
Section: Introductionmentioning
confidence: 99%